

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jun 2026

### Evaluation of the Optimal Dosage for the Efficacy of Submucosal Midazolam Administration to Induce Sedation in Children Undergoing Diagnostic Procedures

#### Protocol summary

##### Study aim

Evaluation of the Optimal Dosage for the Efficacy of Submucosal Midazolam Administration to Induce Sedation in Children Undergoing Diagnostic Procedures

##### Design

A clinical trial without a parallel control group, double-blind, randomized

##### Settings and conduct

The study population was all children undergoing the diagnostic procedure (CT scan) that referred to the emergency department of Kashani and Al-Zahra education training hospitals in Isfahan during 2017-2018. The researcher administered Midazolam with an insulin syringe into the patient's oral mucosa along the molar teeth (4-6 teeth). Then, the onset time of the sedation in the child was recorded. The RAMSAY sedation scale (0-5) was used to measure the sedation level of the child. Moreover, as the child is supposed to be immobilized in the diagnostic procedures, reaching the sedation level of three and four was considered desirable so that the child would have no movement during the therapeutic-diagnostic procedures. In addition, the duration of drug action (from the onset of sedation to the child's return to complete consciousness) was calculated and recorded.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: The age range of over three months up to five years; Children requiring diagnostic procedures such as CT scan; Exclusion criteria: The patients with excessive sensitivity to Benzodiazepines; Medical disorder of shock or blood pressure; Alcohol intoxication; Poor vital signs; Pulmonary diseases; Myasthenia gravis or musculoskeletal disorders

##### Intervention groups

The children were divided into three groups of 33 each. The first group received 0.3 mg / kg midazolam, the second group received 0.4 mg midazolam and the third group received 0.5 mg midazolam.

#### Main outcome variables

The length of the sedative effect

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20171030037093N20**

Registration date: **2019-10-05, 1398/07/13**

Registration timing: **prospective**

Last update: **2019-10-05, 1398/07/13**

Update count: **0**

##### Registration date

2019-10-05, 1398/07/13

##### Registrant information

##### Name

Sadra Ansari pour

##### Name of organization / entity

Shahrekord University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3650 3487

##### Email address

st\_ansari.s@skums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-10-24, 1398/08/02

##### Expected recruitment end date

2020-04-21, 1399/02/02

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the Optimal Dosage for the Efficacy of Submucosal Midazolam Administration to Induce Sedation in Children Undergoing Diagnostic Procedures

**Public title**

Subcutaneous administration of midazolam in pediatric diagnostic procedures

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

The age range of over three months up to five years  
Children requiring diagnostic procedures such as CT scan

**Exclusion criteria:**

The patients with excessive sensitivity to Benzodiazepines  
Medical disorder of shock or blood pressure  
Alcohol intoxication  
Poor vital signs  
Pulmonary diseases  
Myasthenia gravis or musculoskeletal disorders

**Age**

From **3 months** old to **5 years** old

**Gender**

Both

**Phase**

2

**Groups that have been masked**

- Participant
- Investigator

**Sample size**

Target sample size: **99**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The patients randomly selected one of the packets, as a result of which they were divided into three groups, each consisting of 33 patients. Three packets with A, B, and C labels that represented one of the 0.3, 0.4, and 0.5 mg/kg selective doses of Midazolam.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The researcher and the participant have been blinded in this trial. The doses of midazolam are prepared daily by the emergency nurse without the knowledge of the researcher and are available to the researcher. And the participant does not know what drug he is taking.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Isfahan University of Medical Sciences

**Street address**

Isfahn University of Medical Sciences, Hezar jarib st, Isfahan

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Approval date**

2018-01-17, 1396/10/27

**Ethics committee reference number**

IR.MUI.MED.REC.1396.3.829

**Health conditions studied****1****Description of health condition studied**

sedation during procedure

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

The length of the sedative effect

**Timepoint**

From the beginning of sedation to the return of the child to full consciousness

**Method of measurement**

Computing

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Intervention group: The first intervention group received midazolam at a dose of 0.3 mg / kg

**Category**

Treatment - Drugs

**2****Description**

Intervention group: The second intervention group received midazolam at a dose of 0.4 mg / kg

**Category**

Treatment - Drugs

**3****Description**

Intervention group: The third intervention group received midazolam at a dose of 0.5 mg / kg

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Al-zahra hospital

**Full name of responsible person**

Saeed Majidinejad

**Street address**

Sofe Blvd, Isfahan Province, Isfahan

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Phone**

+98 31 3792 7539

**Email**

saeedmajidinejad@yahoo.com

**2****Recruitment center****Name of recruitment center**

Kashani hospital

**Full name of responsible person**

Saeed Majidinejad

**Street address**

Kashani Street, Isfahan Province, Isfahan

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Phone**

+98 31 3792 7539

**Email**

saeedmajidinejad@yahoo.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Ziba Farajzadegan

**Street address**

Isfahan University of Medical Sciences, Hezar jarib Avne

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Phone**

+98 31 3668 0048

**Email**

farajzadegan@med.mui.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Esfahan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Saeed Majidinejad

**Position**

Assistant Professor of Emergency Medicine

**Latest degree**

Specialist

**Other areas of specialty/work**

Emergency Medicine

**Street address**

Department of Emergency Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Phone**

+98 31 3792 7539

**Email**

saeedmajidinejad@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Saeed Majidinejad

**Position**

Assistant Professor of Emergency Medicine

**Latest degree**

Specialist

**Other areas of specialty/work**

Emergency Medicine

**Street address**

Department of Emergency Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Phone**

+98 31 3792 7539

**Email**

saeedmajidinejad@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Saeed Majidinejad

**Position**

Assistant Professor of Emergency Medicine

**Latest degree**

Specialist

**Other areas of specialty/work**

Emergency Medicine

**Street address**

Department of Emergency Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Phone**

+98 31 3792 7539

**Email**

saeedmajidinejad@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Information about the main outcome can be shared.

**When the data will become available and for how long**

Start the access period 4 months after publishing the results

**To whom data/document is available**

Researchers working in academia

**Under which criteria data/document could be used**

Use data to complete clinical trial studies

**From where data/document is obtainable**

Al-Zahra Hospital and Kashani Hospital

**What processes are involved for a request to access data/document**

After the investigation of researcher request and presentation of required documents will be accessible.

**Comments**